Conference Coverage
NewsNetwork
OncLive TV
PEER EXCHANGE
OncLive INSIGHTS

PER is hosting the 2nd Annual International Congress on Oncology Pathology™ | June 23rd in NYCHematologic Malignancies Medical Crossfire in NYC on July 14th! Register today!

SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Neoadjuvant HER2+
More >>
<< View More Conferences

Global Congress on Bladder Cancer

Oncology Conference Multimedia
View more videos >>
Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer
Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer
Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors
Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors
Dr. Konety on Guidelines for the Management of Bladder Cancer
Dr. Konety on Guidelines for the Management of Bladder Cancer
Oncology Conference Articles
Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer
Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer
The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.
Control of Non-Muscle Invasive Bladder Cancer Recurrence With TURBT and Beyond
Control of Non-Muscle Invasive Bladder Cancer Recurrence With TURBT and Beyond
The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.
Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care
Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care
Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.
IMRT Linked With Low Rates of Pelvic Recurrence in Bladder Cancer
IMRT Linked With Low Rates of Pelvic Recurrence in Bladder Cancer
Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence
New Bladder Cancer Monitor Allows Non-invasive Routine Surveillance of NMIBC
New Bladder Cancer Monitor Allows Non-invasive Routine Surveillance of NMIBC
A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.
Chemotherapy Retains Vital Role in Bladder Cancer Care
Chemotherapy Retains Vital Role in Bladder Cancer Care
Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.
Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma
Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma
Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.
Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma
Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma
As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
Publication Bottom Border
Border Publication
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.
 
x